NasdaqCM:PTE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States.


Snowflake Analysis

Fair value with mediocre balance sheet.


Similar Companies

Share Price & News

How has PolarityTE's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PTE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-9.5%

PTE

3.1%

US Biotechs

4.0%

US Market


1 Year Return

-77.5%

PTE

24.2%

US Biotechs

5.0%

US Market

Return vs Industry: PTE underperformed the US Biotechs industry which returned 24.2% over the past year.

Return vs Market: PTE underperformed the US Market which returned 5% over the past year.


Shareholder returns

PTEIndustryMarket
7 Day-9.5%3.1%4.0%
30 Day11.7%7.0%0.9%
90 Day37.8%31.2%29.5%
1 Year-77.5%-77.5%25.5%24.2%7.2%5.0%
3 Year-94.6%-94.6%32.8%28.4%36.2%27.3%
5 Year-80.2%-86.0%0.04%-5.7%65.4%47.0%

Price Volatility Vs. Market

How volatile is PolarityTE's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PolarityTE undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PTE ($1.24) is trading below our estimate of fair value ($18.66)

Significantly Below Fair Value: PTE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PTE is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PTE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PTE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PTE is good value based on its PB Ratio (1.1x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is PolarityTE forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

19.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PTE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PTE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PTE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PTE's revenue (68.1% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: PTE's revenue (68.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PTE's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has PolarityTE performed over the past 5 years?

-36.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PTE is currently unprofitable.

Growing Profit Margin: PTE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PTE is unprofitable, and losses have increased over the past 5 years at a rate of -36.1% per year.

Accelerating Growth: Unable to compare PTE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: PTE has a negative Return on Equity (-191.97%), as it is currently unprofitable.


Next Steps

Financial Health

How is PolarityTE's financial position?


Financial Position Analysis

Short Term Liabilities: PTE's short term assets ($43.7M) exceed its short term liabilities ($11.8M).

Long Term Liabilities: PTE's short term assets ($43.7M) exceed its long term liabilities ($11.0M).


Debt to Equity History and Analysis

Debt Level: PTE's debt to equity ratio (1.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if PTE's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTE has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: PTE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 52.1% each year


Next Steps

Dividend

What is PolarityTE current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PTE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PTE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PTE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PTE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

David Seaburg (50yo)

0.25

Tenure

US$7,500

Compensation

Mr. David B. Seaburg has been Chief Executive Officer of PolarityTE, Inc. since April 2020. He served as President and Member of the Office of Chief Executive at PolarityTE, Inc. since August 26, 2019. Mr ...


Leadership Team

NamePositionTenureCompensationOwnership
David Seaburg
Chief Executive Officer0.25yrUS$7.50k0.88% $404.2k
Edward Swanson
Chief Translational Medicine Officer & Co-Founderno dataUS$400.00k0.10% $46.7k
Paul Mann
Executive Officer0.25yrUS$400.00k1.13% $515.8k
Richard Hague
President & COO0.25yrno data0.78% $355.4k
Jacob Patterson
Interim Chief Financial Officer0.25yrno data0.067% $30.5k
Nikolai Sopko
Chief Scientific Officer and VP of R&D2yrsno datano data
Rich Haerle
Vice President of Investor Relations & Strategy2.17yrsno datano data
Cameron Hoyler
General Counsel and Executive VP of Corporate Development & Strategy3.25yrsno data0.87% $399.5k
Angela Ziegler
Vice President of Marketing & Public Relationsno datano datano data
Alain Adam
Vice President of Sales2yrsno datano data

1.1yrs

Average Tenure

43yo

Average Age

Experienced Management: PTE's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Stephen Milner
Chief Clinical Officer & Member of Clinical Advisory Board3.58yrsno datano data
Peter Cohen
Independent Chairman of the Board0.83yrUS$157.88k0.39% $178.4k
Michael Callahan
Member of Clinical Advisory boardno datano datano data
Jon Mogford
Independent Director3.42yrsUS$148.01k0.21% $94.4k
Michael Grant
Member of Clinical Advisory Board3.58yrsno datano data
Anand Kumar
Member of Clinical Advisory Board3.58yrsno datano data
Jeffry Dyer
Independent Director3.33yrsUS$159.05k0.12% $55.1k
Anthony Tufaro
Member of Clinical Advisory Boardno datano datano data
Trinity Bivalacqua
Member of Clinical Advisory Boardno datano datano data
Chris Nolet
Director0.25yrno datano data

3.4yrs

Average Tenure

63yo

Average Age

Experienced Board: PTE's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49.6%.


Top Shareholders

Company Information

PolarityTE, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PolarityTE, Inc.
  • Ticker: PTE
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$45.742m
  • Shares outstanding: 36.89m
  • Website: https://www.polarityte.com

Number of Employees


Location

  • PolarityTE, Inc.
  • 123 North Wright Brothers Drive
  • Salt Lake City
  • Utah
  • 84116
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PTENasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDDec 2003
NJTCDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2003

Biography

PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. is headquartered in Salt Lake City, Utah. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/04 00:20
End of Day Share Price2020/07/02 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.